Background -An antibiotic adjuvant is a chemical substance used to modify or augment the effectiveness of primary antimicrobial agents against drug-resistant micro-organisms. Its use provides an alternative approach to address the global issue of antimicrobial resistance and enhance antimicrobial stewardship.
Introduction
Otitis externa (OE) is one of the most commonly diagnosed dermatological diseases in dogs with a prevalence of 4.5-13%. [1] [2] [3] Bacterial and yeast pathogens typically associated with canine OE are Staphylococcus pseudintermedius (S. pseudintermedius, formerly S. intermedius), b-haemolytic Streptococcus spp., Pseudomonas aeruginosa, Proteus mirabilis and Malassezia pachydermatis. [4] [5] [6] [7] [8] [9] Infections with these organisms are typically treated with antimicrobial drugs, but there are increasing concerns about bacterial resistance and the requirement for diligent antimicrobial stewardship. 10, 11 Meticillin-resistant S. pseudintermedius (MRSP), which is often multidrug-resistant, [12] [13] [14] as well as multidrugresistant P. aeruginosa strains [15] [16] [17] are frequently isolated from canine OE and/or skin infections. Alarmingly, studies have shown that antimicrobial resistance in the human population, especially in pet owners and veterinarians, can be associated with organisms of canine origin. [18] [19] [20] [21] Therefore, public health risks mandate the prudent use of antimicrobials to safeguard important drugs for human medicine and the search for alternative approaches to treat animal infections. 22, 23 One way of broadening the spectrum of activity of antimicrobial agents is to combine them with an adjuvant. 24, 25 Antimicrobial adjuvants can function in different ways including acting as inhibitors of enzymes that inactivate antibiotics, efflux pump inhibitors, bacterial membrane permeabilizers, biofilm dispersers, inhibitors of antibiotic resistance elements and inhibitors of bacterial cell physiological pathways. 26, 27 Accepted 8 November 2018 Conflicts of interest: Stephen W. Page is a director of Luoda Pharma Pty. Ltd. Darren J. Trott has received research funding from Luoda Pharma, Neoculi, Zoetis, Bayer, Merial, Virbac and Elanco. Sources of funding: Supported by funding from ARC Linkage grant LP130100736 with Luoda Pharma Pty. Ltd as a partner organization This study aimed to determine the in vitro antimicrobial activity of seven nonantibiotic adjuvant agents against common clinical isolates associated with canine OE.
Methods and materials

Antibiotic adjuvants and antibiotics
The seven adjuvants used in this study were monolaurin, monocaprin, N-acetylcysteine (NAC), polymyxin B nonapeptide (PMBN), Tris-ethylenediaminetetraacetic acid (Tris-EDTA), tromethaminehydrochloride (Tris-HCL) and disodium ethylenediaminetetraacetic acid (EDTA). Monolaurin (2-Lauroylglycerol), monocaprin (1-Decanoyl-rac-glycerol), PMBN and NAC (N-acetyl-L-cysteine) were obtained from Sigma-Aldrich (St Louis, MO, USA). Tris-HCL and disodium EDTA were purchased from Promega (Madison, WI, USA).
Monolaurin stock solution was prepared at 259 the highest concentration to be tested in 95% ethanol (VWR International S.A.S.; Fontenay-sous-Bois, France) as described previously. 28 In a preliminary experiment, no inhibitory effect was found on the control bacterial strains when exposed to ≤4% ethanol (highest tested concentration in antimicrobial susceptibility testing) (data not shown). Monocaprin stock solution was prepared at 509 the highest tested concentration in chloroform (Sigma-Aldrich). No inhibitory effect was found when ≤2% chloroform was tested against control bacterial strains in a preliminary experiment. PMBN stock solution was prepared at 109 the highest testing concentration in MilliQ water. These three adjuvants were stored at À80°C until used. On the day of testing, they were diluted to make working solutions of 2,000 lg/mL (monocaprin and monolaurin) and 256 lg/mL (PMBN) with the previously mentioned solvent or diluent. NAC was prepared at 160,000 lg/mL (double the highest concentration to be tested) in cation-adjusted Mueller Hinton Broth (CAMHB) (Becton Dickinson Pty Ltd; Cockeysville, MD, USA). Stock solutions of 1M Tris-HCL and 0.5 M disodium EDTA were prepared in MilliQ water. Tris HCL working solution was prepared in CAMHB at 100 mM (12,200 lg/mL), the highest concentration to be used for preliminary screening. Disodium EDTA working solution was prepared in CAMHB at 20 mM (7,500 lg/mL) for Gram-positive organisms and 80 mM (30,000 lg/mL) for Gram-negative organisms. Tris-EDTA was made by mixing and diluting 1 M Tris-HCL and 0.5M disodium EDTA in CAMHB and then buffered to pH 8.0 with sodium hydroxide (AnalaR â , Merks Pty. Ltd; Victoria, Australia). Tris-EDTA working solution was prepared at a concentration of 100 mM (12,200 lg/mL) Tris-HCL with 10 mM (3,800 lg/mL) disodium EDTA for preliminary screening of ATCC type strains and Gram-positive organisms, and 400 mM (48,500 lg/mL) Tris-HCL with 40 mM (15,000 lg/mL) disodium EDTA for testing of Gram-negative organisms. NAC, Tris-EDTA, Tris-HCL and disodium EDTA were stored at 2-8°C and were ready to be used as working solutions on the day of minimal inhibitory concentration (MIC) testing.
Ampicillin, 99.4% purity (Sigma-Aldrich) was used as a control for Gram-positive organisms. Enrofloxacin, 99.8% purity (Sigma-Aldrich) was used as a control for Gram-negative organisms. Amphotericin B, 250 lg/mL (Sigma-Aldrich) was used as the control for fungal organisms. Both ampicillin and enrofloxacin stock solutions were prepared at 3.2 and 12.8 mg/mL, respectively, and stored at À80°C until used. Amphotericin B was stored as its original solution at À20°C and thawed for use on the day of antifungal susceptibility testing.
Bacterial and yeast isolates
One hundred and ten clinical isolates from cases of canine OE were collected from diagnostic laboratories throughout Australia. These organisms were speciated using biochemical testing and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) mass spectrometry (Bruker; Preston, Victoria, Australia). These isolates comprised 17 meticillin-susceptible Staphylococcus pseudintermedius (MSSP) and 13 MRSP obtained from the first national survey of antimicrobial resistance in animal pathogens conducted in Australia, 29 and 20 each of b-haemolytic Streptococcus 
Antimicrobial susceptibility testing
The antimicrobial susceptibility of each isolate was determined using minimal inhibitory concentration (MIC) microdilution methodology as recommended by the Clinical and Laboratory Standards Institute (CLSI). 32 Briefly, bacterial isolates were subcultured on 5% Sheep
Blood Columbia Agar (Thermo Fisher Scientific; Victoria, Australia) and incubated overnight at 37°C, with 5% CO 2 supplemented for streptococcal isolates. A bacterial suspension for each isolate was prepared in phosphate buffered saline Oxoid Limited; Basingstoke, Hampshire, UK. and adjusted to 0.5 McFarland standard. Two-fold serial dilution of each adjuvant working solution was performed with 90 lL CAMHB in 96-well microtitre antimicrobial challenge plates (Nunclon TM Delta Surface, Thermo Fisher Scientific, Roskilde, Denmark). Finally, 10 lL of the bacterial inoculum was added to the 90 lL adjuvant solution to achieve a final bacterial concentration of 5 9 10 5 colony forming units (cfu)/mL. The final tested concentration ranges of each adjuvant is shown in Table 1 . Antimicrobial challenge plates for streptococcal isolates were prepared using CAMHB supplemented with 5% lysed sheep blood. All isolates and control strains were tested in duplicate. Negative growth controls contained only CAMHB and positive growth controls contained CAMHB and bacterial suspension. Bacterial growth was assessed visually after overnight incubation at 37°C and MIC was determined as the lowest concentration of adjuvant that completely inhibited the growth of the organism. The MIC range (minimum and maximum), MIC 50 and MIC 90 were recorded and calculated for each of the clinical bacterial groups. The MIC 50 and MIC 90 values were defined as the lowest concentrations of adjuvant at which 50% and 90% of the isolates were inhibited, respectively.
Antifungal susceptibility testing
The antifungal susceptibility of M. pachydermatis isolates was performed using a modified CLSI broth microdilution method. 30, 31 Briefly, isolates were inoculated onto Sabouraud's dextrose agar (SDA) supplemented with 1% Tween 80 (Sigma-Aldrich) 33, 34 and incubated for 72 h at 35°C. Yeast isolates were suspended in Sabouraud's dextrose broth (SDB) (Oxoid TM ) supplemented with 1% Tween 80 to obtain a uniform yeast suspension with an optical density (OD) between 0.2 and 0.3 at 600 nm wavelength (Eppendorf BioPhotometer plus; Hamburg, Germany) and further diluted 1:100 in the same medium. Antifungal challenge plates were prepared by creating twofold serial dilutions of the adjuvant working solution in 150 lL SDB supplemented with 1% Tween 80 in 96-well microtiter plates (Nunclon TM Delta Surface; Thermo Fisher Scientific). Thereafter, 50 lL of yeast suspension was added to 150 lL of the adjuvant solution to create a final inoculum concentration of 2-2.5 9 10 3 cfu/mL and adjuvant (NAC, Tris-EDTA and disodium EDTA) concentrations as shown in Table 1 . The MIC end-point was determined every 24 h (up to 72 h) using a combination of two methods: visual end-point reading of more than or equal to 50% growth inhibition (prominent decrease in turbidity) compared with the positive growth control and spectrophotometric end-point reading of OD 570 nm less or equal to 50% of the positive growth control. 30 The MICs were reported as described above for bacterial antimicrobial susceptibility testing. Precipitation also was observed at concentrations beyond 1,000 lg/mL during MIC testing of monocaprin. Based on the antimicrobial activities found during the preliminary screening, three adjuvants (NAC, Tris-EDTA and disodium EDTA) were chosen for further antimicrobial susceptibility testing against the clinical bacterial and yeast isolates (Table 2 ) and quality control strains (Table S1 ). NAC was effective against all 110 bacterial and yeast isolates with MICs ranging from 2,500 to 10,000 lg/mL. Both Staphylococcus and Streptococcus clinical isolates showed similar values in MIC range, MIC 50 and MIC 90 for Tris-EDTA and disodium EDTA at 1,500/470 and 470 lg/mL, respectively. There was no difference in results between MSSP and MRSP for all three adjuvants. The Tris-EDTA MIC range was one to two dilutions lower for Pseudomonas clinical and control strains compared to the screening results in Table 1 . Proteus mirabilis isolates were more susceptible to disodium EDTA (MIC 90 of 930 lg/mL) than P. aeruginosa (MIC 90 of 7,500 lg/mL). Compared to both Gram-positive and Gram-negative clinical isolates, M. pachydermatis yeast isolates were most susceptible to Tris-EDTA and disodium EDTA with a MIC range of 95/30-190/60 lg/mL and 30-120 lg/mL, respectively.
Results
Consistent confluent growth was observed in all of the positive growth control wells and there was no growth in any of the negative growth control wells. MICs of ATCC type strains against selected control antimicrobials were within CLSI ranges (Table S2) .
Discussion
This study has demonstrated the in vitro antimicrobial activity of NAC, Tris-EDTA and disodium EDTA against pathogenic Gram-positive (including MRSP), Gram-negative bacteria and M. pachydermatis isolated from cases of canine OE. The other adjuvants tested had either a limited spectrum or no antimicrobial activity.
N-acetylcysteine is a known mucolytic and nonantibiotic agent with bactericidal activity. 35 Its proposed mode of action is to competitively inhibit the uptake of amino acids such as cysteine by bacterial cells or to react with the bacterial cell proteins with its own sulfhydryl group. 36 It is used as a flushing solution to physically remove biofilm as part of the management of canine OE. 37 Studies related to human respiratory and urinary tract diseases have described the combination of NAC with other antibiotics such as carbenicillin, fosfomycin and ciprofloxacin to potentiate the antimicrobial activity of these antibiotics, to increase the inhibitory effect on biofilm formation and to eradicate mature biofilms. [38] [39] [40] In this study, NAC had a comprehensive range of antimicrobial activities against both Gram-positive and Gram-negative bacteria and yeast isolates associated with canine OE. In comparison to a previous study, 41 in which the NAC MIC ranged from 5,000 to 20,000 lg/mL, our MICs were typically one-to two-fold lower for all of the isolates except b-haemolytic Streptococcus (2,500-5,000 lg/mL) and 90% of each clinical isolate cohort was inhibited at 5,000 lg/mL. Conversely, an older study 42 observed that P. aeruginosa growth curve and inhibition in the presence of NAC were both dose-and inoculum size-dependent; consequently, they were able to detect a NAC MIC of P. aeruginosa at a lower concentration range (2-20 lg/mL). Another study used NAC as an adjunctive therapy against fluoroquinolone/ciprofloxacin-resistant P. aeruginosa strains associated with human chronic otitis media at concentrations ≥0.5% or 5,000 lg/mL. 43 Taken together, our results and those from previous studies suggest that NAC could potentially be a useful antimicrobial adjuvant that could be safely incorporated in the treatment and management of OE in dogs, especially in cases associated with antimicrobial resistance.
Tris-EDTA is a common ingredient found in ear cleaners or rinses to remove ear debris, reduce microbial load and increase the susceptibility of otic pathogens to topical antimicrobial therapy for canine OE. 37, 44 There is a significant literature on Tris-EDTA and disodium EDTA that describes these bacteriostatic agents as potentiating other antimicrobial agents [45] [46] [47] or assesses their antibacterial activity as a part of a formulation or poly-pharmaceutical commercial product. 48, 49 Tris-buffer enhances EDTA's ability to chelate and remove divalent cations that are critically important in maintaining the integrity of the lipopolysaccharide cell wall. Disruption leads to solubilization of the cell wall and increases the permeability of the outer membrane of resistant Gram-negative organisms to primary antimicrobial agents. [50] [51] [52] We confirmed in the present study that the antibacterial activity of Tris-EDTA against the ATCC type strains was dependent on the presence of disodium EDTA as no activity was observed with Tris-HCL alone. Furthermore, for P. aeruginosa, there was a significant reduction in the MIC 50 (two times lower) and MIC 90 (eight times lower) for disodium EDTA in the presence of Tris-HCL compared to disodium EDTA used alone. However, this was not the case for P. mirabilis isolates, in which disodium EDTA was essentially as effective on its own. Proteus mirabilis clinical isolates also were four to eight times more susceptible to disodium EDTA than P. aeruginosa clinical isolates. In our study, the MIC range for Tris-EDTA against canine otic Pseudomonas isolates was comparatively lower (1,500/ 470-3,000/930) than those reported previously, 15 with the range of 2,200/600-8,900/2,400 lg/mL. The antimicrobial activity of disodium EDTA against both Gram-positive and Gram-negative ATCC strains in our study was quite close to the findings in a previous study. 53 To the best of the authors' knowledge, this is the first study to demonstrate in vitro antifungal activity of disodium EDTA and Tris-EDTA against otic Malassezia pachydermatis from dogs using the MIC methodology. No previous report was identified which described the in vitro susceptibility of yeast to EDTA or Tris-EDTA alone. Previous studies only reported the anti-yeast activity of an otic cleaner which contained disodium EDTA or Tris-EDTA as one of a number of other ingredients, with inhibitory activity recorded in either the effect of growth reduction (cfu/mL) 54 or dilution ratio. 48, 49 Our results also provide a clear comparison of the efficacy of disodium EDTA against yeast compared to Gram-positive and Gram-negative bacteria. With reference to MIC 90 , M. pachydermatis was eight times more susceptible to P. mirabilis and 62.59 more susceptible than P. aeruginosa, but only four times more susceptible than S. pseudintermedius and Streptococcus spp.
The results of this study have shown that NAC, Tris-EDTA and disodium EDTA demonstrated extensive in vitro antimicrobial activities against Gram-positive organisms (including the 13 isolates of MRSP), Gramnegative and yeast isolates associated with canine OE. If antimicrobial results are confirmed in vivo, these three agents could be used as antibiotic adjuvants or potentiating agents for other antibiotics to treat Gram-negative and multidrug-resistant bacterial infections. In alignment with Table 2 . MIC range, MIC 50 Isolates included meticllin-susceptible Staphylococcus pseudintermedius (n = 17), meticillin-resistant Staphylococcus pseudintermedius (n = Refer to Table 1 for the range of concentrations tested.
the principles of antimicrobial stewardship, this might spare the use of important human medicines and prevent the ongoing development of antimicrobial resistance. There also is the potential for adjuvants to be incorporated with other antimicrobials in an otic formulation as a multimodal approach to treating mixed ear infections in dogs. Further studies are underway to test this hypothesis.
Animales/aislamientos -se analizaron cepas tipo y aislamientos cl ınicos (n = 110) de OE canina, que inclu ıan Staphylococcus pseudintermedius, Streptococcus spp. b-hemol ıtico, Pseudomonas aeruginosa, Proteus mirabilis y Malassezia pachydermatis. M etodos -se analizaron las actividades antimicrobianas de monolaurina, monocaprina, N-acetilciste ına (NAC), polimixina B nonap eptido, Tris-EDTA, Tris-HCL y EDTA dis odico utilizando la metodolog ıa de microdiluci on de acuerdo con las pautas CLSI.
Resultados -N-acetilciste ına, Tris-EDTA y EDTA dis odico tuvieron actividad antimicrobiana contra cepas tipo y pat ogenos oticos aislados de campo. Los otros adyuvantes probados tuvieron eficacia limitada o no existente. La NAC ten ıa un rango de concentraci on inhibitoria m ınima (CIM) de 2,500 a 10,000 lg/ml para los diversos organismos. Los aislamientos de Pseudomonas aeruginosa fueron ocho veces m as susceptibles al EDTA dis odico en presencia de Tris-HCL en comparaci on con el EDTA dis odico solo. Los aislados de Malassezia pachydermatis fueron m as susceptibles a Tris-EDTA (MIC90 = 190/60 lg/mL) y EDTA dis odico (MIC90 = 120 lg/mL). Conclusiones y relevancia cl ınica -la N-acetilciste ına, Tris-EDTA y EDTA dis odico tienen actividad antimicrobiana intr ınseca y representan adyuvantes prometedores que podr ıan usarse para mejorar la eficacia de los antibi oticos existentes contra las infecciones bacterianas Gram-negativas y resistentes a m ultiples f armacos. Estos agentes podr ıan combinarse con otros agentes antimicrobianos en un enfoque multimodal para infecciones de o ıdo mixtas en perros. 
